Sponsored by:
Accelerator™ Drug Development: Streamlining Preclinical Pathways for a Fast Transition to First-in-Human Trials
For emerging biotech companies, the path from preclinical development to first-in-human (FIH) trials can define the future of a therapy. Challenges such as regulatory hurdles, incomplete API characterization,and inefficient study design often lead to costly delays and lost momentum.
One biotech developer encountered these issues while preparing a novel therapeutic for clinical testing. With poorly defined release methods and site selection inefficiencies, they faced potential delays of up to 18 months and over $1 million in additional costs.
Discover how Thermo Fisher Scientific’s Accelerator™ Drug Development enabled them to overcome these obstacles streamlining early development, accelerating FIH readiness, and ensuring faster progress with greater confidence.
